Building the next layer of GLP-1 therapy
We are building relationships with investors, pharmaceutical companies and development partners to advance HT-101 through clinical validation and toward strategic partnering.
Our Supporters
We are proud to be supported by leading organizations that contribute to the development of HT-101 and help advance its journey from research to clinical application. Their support strengthens our scientific capabilities, development activities, and broader impact.
Supporter
Our activities are supported by the Ministry of Economic Affairs and Communications through the DeepTech Accelerator programme. https://startupestonia.ee/focus-areas/deeptech/
Supporter
Supporting preclinical work and first proof-of-concept clinical study evaluating HT-101 for reducing gastrointestinal side effects associated with GLP-1 receptor agonist treatment. https://ut.ee/en
Collaboration Opportunities
We are building relationships with investors, pharmaceutical companies and development partners to advance HT-101 through clinical validation and toward strategic partnering.
Supporting further clinical development
Strategic development and licensing opportunities
Accelerating translation of HT-101
Partnership Inquiry
We are building strategic relationships with investors, pharmaceutical companies, clinical research organisations and development partners to advance our therapeutic concept through clinical validation and toward future strategic partnerships.